Is EIKN or ZBIO more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Zenas BioPharma N/A -122.45% -58.04%

Does the media favor EIKN or ZBIO?

In the previous week, Zenas BioPharma had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Zenas BioPharma and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.67 beat Zenas BioPharma's score of 0.56 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NUVB or EIKN?

In the previous week, Nuvation Bio had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Nuvation Bio and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.67 beat Nuvation Bio's score of 0.59 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADMA or EIKN?

In the previous week, Eikon Therapeutics had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.51 beat Eikon Therapeutics' score of 0.67 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or EIKN?

In the previous week, Agios Pharmaceuticals had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 5 mentions for Eikon Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Eikon Therapeutics' score of 0.67 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MESO or EIKN more profitable?

Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Eikon Therapeutics N/A N/A N/A

Does the media prefer MESO or EIKN?

In the previous week, Eikon Therapeutics had 1 more articles in the media than Mesoblast. MarketBeat recorded 5 mentions for Eikon Therapeutics and 4 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Eikon Therapeutics' score of 0.67 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eikon Therapeutics (EIKN) Competitors

$8.13 -0.85 (-9.47%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$8.21 +0.08 (+0.98%)

As of 09/23/2026 07:30 PM Eastern

Compare

EIKN vs. ZBIO, NUVB, ADMA, AGIO, and MESO

Should you buy Eikon Therapeutics stock or one of its competitors? Eikon Therapeutics's main competitors and comparable companies include Zenas BioPharma (ZBIO), Nuvation Bio (NUVB), ADMA Biologics (ADMA), Agios Pharmaceuticals (AGIO), and Mesoblast (MESO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eikon Therapeutics compare to Zenas BioPharma?

Eikon Therapeutics (NASDAQ:EIKN) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Eikon Therapeutics' return on equity of 0.00% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Zenas BioPharma	N/A	-122.45%	-58.04%

Eikon Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Zenas BioPharma	$10M	193.13	-$377.74M	-$8.99	N/A

Eikon Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 207.50%. Zenas BioPharma has a consensus price target of $45.71, indicating a potential upside of 54.28%. Given Eikon Therapeutics' higher probable upside, equities analysts clearly believe Eikon Therapeutics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zenas BioPharma had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Zenas BioPharma and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.67 beat Zenas BioPharma's score of 0.56 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eikon Therapeutics beats Zenas BioPharma on 8 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

61.7% of Nuvation Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eikon Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Eikon Therapeutics' return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Eikon Therapeutics	N/A	N/A	N/A

Nuvation Bio has higher revenue and earnings than Eikon Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$169.90M	11.77	-$204.63M	-$0.44	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Nuvation Bio presently has a consensus price target of $13.00, indicating a potential upside of 128.27%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 207.50%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Nuvation Bio had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Nuvation Bio and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.67 beat Nuvation Bio's score of 0.59 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nuvation Bio beats Eikon Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Eikon Therapeutics compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

ADMA Biologics has a net margin of 32.98% compared to Eikon Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Eikon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Eikon Therapeutics	N/A	N/A	N/A

ADMA Biologics has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.26	$146.93M	$0.70	13.86
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, Eikon Therapeutics had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.51 beat Eikon Therapeutics' score of 0.67 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 92.44%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 207.50%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

75.7% of ADMA Biologics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ADMA Biologics beats Eikon Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Eikon Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Agios Pharmaceuticals presently has a consensus target price of $41.75, indicating a potential upside of 22.11%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 207.50%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Agios Pharmaceuticals had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 5 mentions for Eikon Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Eikon Therapeutics' score of 0.67 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Eikon Therapeutics' return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Eikon Therapeutics	N/A	N/A	N/A

Eikon Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Summary

Eikon Therapeutics beats Agios Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Eikon Therapeutics had 1 more articles in the media than Mesoblast. MarketBeat recorded 5 mentions for Eikon Therapeutics and 4 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Eikon Therapeutics' score of 0.67 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast currently has a consensus price target of $39.00, suggesting a potential upside of 155.07%. Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 207.50%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mesoblast has higher revenue and earnings than Eikon Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.51	-$57.50M	-$0.28	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Eikon Therapeutics	N/A	N/A	N/A

Summary

Mesoblast and Eikon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$486.40M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.99	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	N/A	15.40	10.47	6.32
Net Income	-$324.25M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-5.47%	-1.70%	-0.67%	0.17%
1 Month Performance	-27.15%	-6.17%	-3.17%	-3.27%
1 Year Performance	N/A	30.67%	15.14%	5.58%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	3.293 of 5 stars	$8.13 -9.5%	$25.00 +207.5%	N/A	$486.40M	N/A	N/A	384
ZBIO Zenas BioPharma	2.1546 of 5 stars	$30.92 -3.1%	$45.71 +47.8%	+56.3%	$2.01B	$10M	N/A	167	News Coverage
NUVB Nuvation Bio	2.9873 of 5 stars	$5.72 -3.8%	$13.00 +127.5%	+77.1%	$2.00B	$169.90M	N/A	305
ADMA ADMA Biologics	3.2384 of 5 stars	$8.84 -3.2%	$18.67 +111.1%	-39.3%	$1.97B	$510.17M	12.59	647
AGIO Agios Pharmaceuticals	3.33 of 5 stars	$33.05 -0.5%	$41.25 +24.8%	-9.7%	$1.97B	$54.03M	N/A	540	Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. ZBIO, NUVB, ADMA, AGIO, and MESO

How does Eikon Therapeutics compare to Zenas BioPharma?

Summary

How does Eikon Therapeutics compare to Nuvation Bio?

Summary

How does Eikon Therapeutics compare to ADMA Biologics?

Summary

How does Eikon Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Eikon Therapeutics compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. ZBIO, NUVB, ADMA, AGIO, and MESO

How does Eikon Therapeutics compare to Zenas BioPharma?

Is EIKN or ZBIO more profitable?

Which has preferable valuation & earnings, EIKN or ZBIO?

Do analysts recommend EIKN or ZBIO?

Does the media favor EIKN or ZBIO?

Summary

How does Eikon Therapeutics compare to Nuvation Bio?

Do institutionals & insiders believe in NUVB or EIKN?

Is NUVB or EIKN more profitable?

Which has preferable valuation & earnings, NUVB or EIKN?

Do analysts recommend NUVB or EIKN?

Does the media prefer NUVB or EIKN?

Summary

How does Eikon Therapeutics compare to ADMA Biologics?

Is ADMA or EIKN more profitable?

Which has stronger earnings and valuation, ADMA or EIKN?

Does the media prefer ADMA or EIKN?

Do analysts rate ADMA or EIKN?

Do insiders and institutionals have more ownership in ADMA or EIKN?

Summary

How does Eikon Therapeutics compare to Agios Pharmaceuticals?

Do analysts rate AGIO or EIKN?

Does the media favor AGIO or EIKN?

Is AGIO or EIKN more profitable?

Which has preferable valuation and earnings, AGIO or EIKN?

Summary

How does Eikon Therapeutics compare to Mesoblast?

Does the media prefer MESO or EIKN?

Do analysts prefer MESO or EIKN?

Which has higher valuation & earnings, MESO or EIKN?

Do insiders and institutionals hold more shares of MESO or EIKN?

Is MESO or EIKN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools